Cagrilintide works through amylin receptors (the CTR-RAMP complex), which are distinct from GLP-1 receptors but produce powerful appetite suppression through different signaling pathways, particularly in the area postrema of the brainstem
Abstract Purpose This meta-analysis aimed to assess the efficacy and safety of once-weekly semaglutide among adults with overweight or obesity
Incorrect claims can result in penalty charges
The point is to recognise that the risk is elevated and to respond appropriately if symptoms appear
[1] A potential tapering approach, based solely on clinical judgment rather than formal guidelines or comparative studies, might involve reducing the dose by one step every 46 weeks
Dosage will be determined by your healthcare provider depending on your medical history, lifestyle, and weight management goals